Legend Biotech (LEGN) Tops Q2 EPS by 15c

Legend Biotech (NASDAQ: LEGN) reported Q2 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $255.06 million versus the consensus estimate of $234.23 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Syntholene Energy plans $1.5M private placement at $0.45 per unit
• DHT Holdings Q2 TCE earnings estimated at $126,700 per day